RxDoctor Payments Data

Daniel Gonzalez, MD

Rheumatology · Little Rock, ARNPI 1962994608

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 487 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 22.7% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $4,520, more than ten times the $55 reported in 2020.

$11,958in general payments, 2019–2025

Across 487 payments — averaging $24.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Amgen$2K
  • UCB, Inc.$1K
  • AstraZeneca$1K
  • GSK$768
  • Pfizer$642
  • plus $3K from 23 others

What the payments were for

  • Food & beverage$11,958100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,958 in reported general payments places this provider in the 70th percentile of 48 rheumatology providers in Arkansas.

See all rheumatology providers in Arkansas

Medicare billing

Part B allowed, 2024
$71,595
Medicare patients
249
Services billed
2,855

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MethotrexateMethotrexate Sodium240$6,396
Hydroxychloroquine Sulfate195$5,127
Sulfasalazine DrSulfasalazine117$5,062
Leflunomide60$1,825
Prednisone234$1,715
Sulfasalazine26$517
Allopurinol46$381
Colchicine17$368
Azathioprine11$363
Gabapentin47$298
Diclofenac Sodium18$268
Tramadol Hcl13$211
Alendronate Sodium14$202
Ondansetron OdtOndansetron11$193
Folic Acid32$179

Paid to pharmacies, not to this prescriber.

Other rheumatology in Little Rock

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →